Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Ultragenyx Pharmaceutical’s reported figures.
Plus components not separately reported this period.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
FAQ
- What is Ultragenyx Pharmaceutical's EBIT?
- Ultragenyx Pharmaceutical (RARE) reported EBIT of -$75M in Q2 2026.
- How has Ultragenyx Pharmaceutical's EBIT changed year-over-year?
- Ultragenyx Pharmaceutical's EBIT increased by 30.6% year-over-year, from -$108M to -$75M.
- What is the long-term trend for Ultragenyx Pharmaceutical's EBIT?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's EBIT has grown at a 8.8% compound annual growth rate (CAGR), from -$381.74M to -$535.17M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Ultragenyx Pharmaceutical's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude